All In Biotech

Drug Trial Radar · NCT07051993

A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants

A Phase 1, Open-Label, Randomized, Crossover, Two-Part Study to Evaluate the Relative Bioavailability of Two ZN-A-1041 Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 Tablet(s) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jun 27, 2025

Primary completion

Jul 12, 2025

Study completion Jul 12, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, randomized, two-part study to evaluate the relative bioavailability (rBA) of two tablet formulations compared to the capsule formulation of ZN-A-1041 (Part 1). Part 2 of the study will evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation. No participants were enrolled in Part 2 of the study as it has been cancelled.

Conditions

  • Healthy Participants

Interventions

  • ZN-A-1041Drug

    Participants will be administered either a ZN-A-1041 capsule or a tablet orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax)Time frame: Days 1-12 (Part 1)
  2. Area Under the Concentration-Time curve from Hour 0 to the Last Measurable Concentration (AUC0-t)Time frame: Days 1-12 (Part 1)
  3. AUC Extrapolated to Infinity (AUC0-inf)Time frame: Days 1-12 (Part 1)
  4. Geometric Mean Ratio and Associated 90% Confidence Interval (CI) of CmaxTime frame: Days 1-12 (Part 1)
  5. Geometric Mean Ratio and Associated 90% CI of AUC0-tTime frame: Days 1-12 (Part 1)
  6. Geometric Mean Ratio and Associated 90% CI of AUC0-infTime frame: Days 1-12 (Part 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Leeds CRU

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.